PFM
PTGX icon

Privium Fund Management’s Protagonist Therapeutics PTGX Stock Holding History

Privium Fund Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-114,024
Closed -$3.3M – 135
2024
Q1 		$3.3M Buy
+114,024
New +$3.1M 0.88% 28

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Privium Fund Management's PTGX Position: Q2 2024 in Review

Privium Fund Management sold out of Protagonist Therapeutics (PTGX) in Q2 2024, closing a stake of 114,024 shares — an estimated $3.3M sold.

Privium Fund Management first reported a position in PTGX in Q1 2024 and held it in 1 quarter. The position peaked at $3.3M in Q1 2024. 188 funds tracked by Wall St. Rank hold PTGX as of Q2 2024.

  • Privium Fund Management reported no remaining Protagonist Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Privium Fund Management sold 114,024 Protagonist Therapeutics shares in Q2 2024, an estimated $3.3M.
  • Privium Fund Management first reported a position in Protagonist Therapeutics in Q1 2024 and held it in 1 quarter.
  • Privium Fund Management's Protagonist Therapeutics position peaked at $3.3M in Q1 2024.
  • 188 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2024.

Based on Privium Fund Management's 13F filing for Q2 2024, filed 1 Aug 2024.